Maja Agung Latexindo Tbk. logo

Maja Agung Latexindo Tbk. (SURI)

Market Closed
17 Jul, 08:49
IDX IDX
Rp
67. 00
+1
+1.5152%
Rp
- Market Cap
- P/E Ratio
5% Div Yield
3.86M Volume
- Eps
Rp 66
Previous Close
Add Transaction
Day Range
66 68
Year Range
50 152
Want to track SURI and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

SURI closed yesterday higher at Rp67, an increase of 1.5152% from Thursday's close, completing a monthly increase of 15.5172% or Rp9. Over the past 12 months, SURI stock lost -26.3736%.
SURI pays dividends to its shareholders, with the most recent payment made on Jun 30, 2026. The next estimated payment will be in In 2 months on Sep 30, 2026 for a total of Rp0.68.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on ARCA (USD).

SURI Chart

Maja Agung Latexindo Tbk. (SURI) FAQ

What is the stock price today?

The current price is Rp67.00.

On which exchange is it traded?

Maja Agung Latexindo Tbk. is listed on IDX.

What is its stock symbol?

The ticker symbol is SURI.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 5%.

What is its market cap?

As of today, no market cap data is available.

Has Maja Agung Latexindo Tbk. ever had a stock split?

No, there has never been a stock split.

Maja Agung Latexindo Tbk. Profile

Capital Markets Industry
Financials Sector
- CEO
IDX Exchange
ID1000200207 ISIN
US Country
- Employees
25 Jun 2026 Last Dividend
- Last Split
- IPO Date

Overview

The fund described is an actively managed exchange-traded fund (ETF) that specializes in the health and life sciences sector. Concentrating its investments heavily within the biotechnology, pharmaceuticals, healthcare technology, and life science tools and services industries, the fund adopts a strategy that involves investing more than 25% of its net assets in these areas. It operates under the guidance of a Sub-Adviser who executes an opportunistic multi-asset strategy. This approach allows for investment across a broad range of security types, including common stock, preferred stock, convertible bonds, structured notes, corporate notes and bonds, as well as ETFs that majorly invest in similar types of securities. By design, this fund is non-diversified, aligning its focus on a more concentrated portfolio within the aforementioned sectors.

Products and Services

  • Common Stock Investments

    The fund invests in the common stock of companies within the biotechnology, pharmaceuticals, healthcare technology, and life science tools and services industries. This encompasses equity stakes in businesses that are pioneering in medical research, drug development, and innovative health solutions.

  • Preferred Stock Investments

    As part of its diversified approach, the fund also allocates assets in preferred stocks within the health and life science sector. Preferred stocks provide a potential advantage of fixed dividends, aligning with the fund's goal of achieving steady returns from its holdings in the healthcare industry.

  • Convertible Bonds

    The investment strategy extends to convertible bonds issued by corporations within the targeted industries. These securities offer the fund the flexibility to convert debt into a predetermined number of common or preferred shares, typically at the discretion of the bondholder, which can be an attractive option during periods of stock market growth.

  • Structured Notes

    Structured notes, combining bonds and additional derivatives, form a part of the fund’s portfolio. These are tailored to reflect the performance of specific securities, indexes, or commodities within the healthcare and life sciences sectors, offering unique risk-return profiles.

  • Corporate Notes and Bonds

    Direct investments in corporate notes and bonds issued by companies within the fund's focus areas provide a stream of income through interest payments. This adds an element of fixed-income security to the fund’s investment strategy, balancing its overall risk.

  • ETFs in Health and Life Sciences

    Finally, the fund allocates part of its assets to other ETFs that primarily invest in securities from the biotechnology, pharmaceutical, healthcare technology, and life science tools and services industries. This allows for enhanced diversification and access to a broader array of securities within the targeted sectors.

Contact Information

Address: 10845 Griffith Peak Drive
Phone: 614-469-3294